UFP Technologies price to free cash flow UFPT
Market value divided by free cash flow over the last twelve months, since 2012.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 18.3×
- Feb 2026
- 10-year median
- 27.3×
- 10-year range
- 10.3× to 461×
- Peer median
- 26.7×
UFP Technologies' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.
It was last meaningful in Feb 2026, at 18.3×.
On the days it had one over the last ten years, its median was 27.3×, from 10.3× in Mar 2020 to 461× in Aug 2022.
Price to free cash flow over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 18.3× | 18.3× | 23.3× |
| 2025 | 20.6× | 18.9× | 46.4× |
| 2024 | 41.7× | 34.0× | 64.9× |
| 2023 | 36.7× | 30.4× | 272× |
| 2022 | 461× | 27.0× | 461× |
| 2021 | 32.3× | 16.3× | 32.3× |
| 2020 | 16.5× | 10.3× | 17.0× |
| 2019 | 14.6× | 12.7× | 25.1× |
| 2018 | 23.1× | 21.9× | 267× |
| 2017 | 26.1× | 21.9× | 177× |
| 2016 | 178× | 60.7× | 182× |
| 2015 | n/m a value too high to mean anything | ||
| 2014 | 24.4× | 16.1× | 27.6× |
| 2013 | 22.4× | 21.4× | 39.8× |
| 2012 | 28.2× | 15.5× | 28.6× |
Against its peers
Companies in Medical - Instruments & Supplies nearest UFP Technologies' size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| UFPTUFP Technologies | n/m |
| INSPInspire Medical Systems | 17.6× |
| LMATLemaitre Vascular | 26.2× |
| ATRCAtriCure | 56.5× |
| WRBYWarby Parker | 147× |
| EYENational Vision | 30.1× |
| NVSTEnvista | 15.3× |
| CDRECadre | 16.4× |
| ICUIICU Medical | 27.3× |
| BVSBioventus | 13.3× |
| BMIBadger Meter | 29.2× |
| Peer median | 26.7× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on UFP Technologies
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.